Clinical Trial

ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2024 (before its estimated December 12, 2025 completion). Its status may not reflect the trial's current state.
Summary
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with head and neck squamous cell carcinoma and other solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-17; most recent amendment 2024-08-19.
Status change: Not Yet Recruiting → Recruiting 2024-02-26
Trial Details
NCT Number NCT06007729
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 170 participants
Start Date 2023-12-18
Primary Completion 2025-12-12 (estimated)
Study Completion 2027-12-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-20